Catheter Precision Secures Tender From Leading Hospital in Hungary

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced that its VIVO system secured a significant multi-year tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary, marking the company’s first installation in Hungary and a push into Central and Eastern Europe. The award was won in partnership with local distributor Fototronic. Installation is anticipated in Q1 2026. The release positions the VIVO system — a non-invasive 3D ventricular tachycardia localization tool used before ablation — as gaining wider adoption following recent multi-year agreements in France, supporting the company’s European expansion strategy.

Positive

• First installation in Hungary at Szeged University Hospital
• Installation scheduled for Q1 2026
• Multi-year tender secured with local partner Fototronic
• Adds to recent multi-year agreements in France supporting EU adoption

Negative

• None.

News Market Reaction

+13.33% 7.1x vol

13 alerts

+13.33% News Effect

+12.9% Peak Tracked

-12.0% Trough Tracked

+$498K Valuation Impact

$4M Market Cap

7.1x Rel. Volume

On the day this news was published, VTAK gained 13.33%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.9% during that session. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $498K to the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Installation timeline: Q1 2026 3D localization: 3D

2 metrics

Installation timeline Q1 2026 VIVO system installation expected at Szeged University Hospital

3D localization 3D Non-invasive 3D localization of ventricular tachycardia prior to ablation

Market Reality Check

Price: $2.30 Vol: Volume 39,700 vs 20-day a...

normal vol

$2.30 Last Close

Volume Volume 39,700 vs 20-day average 53,147, about 25% below typical trading activity. normal

Technical Price $2.704 is trading below the 200-day MA at $4.15, reflecting a longer-term downtrend pre-announcement.

Peers on Argus

While VTAK was up 7.53%, peers NUWE (-11.55%), BBLG (-6.26%), BJDX, VERO and NAO...

While VTAK was up 7.53%, peers NUWE (-11.55%), BBLG (-6.26%), BJDX, VERO and NAOV all showed declines, indicating a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	International tender win	Positive	+13.3%	First VIVO tender in Hungary supporting Central and Eastern Europe expansion.
Dec 01	Product launch	Positive	-3.3%	LockeT commercial launch in Switzerland with initial clinical use and positive feedback.
Nov 25	Reimbursement change	Positive	+12.1%	New ASC reimbursement for EP ablation seen as opportunity for LockeT uptake.
Nov 20	International uptake	Positive	-9.9%	Rapid LockeT adoption in five South African hospitals with reorders reported.
Nov 13	Earnings update	Negative	-10.9%	Q3 2025 results showing small revenue base, significant losses and growing deficit.

Pattern Detected

Commercial and market-expansion announcements often produced sharp but directionally mixed moves, while more financially focused disclosures with losses tended to see negative reactions.

Recent Company History

This announcement continues Catheter Precision’s push to grow its European footprint, following LockeT’s Switzerland launch on Dec 1, 2025 and rapid adoption in South Africa reported on Nov 20, 2025. A U.S. reimbursement change for ambulatory EP ablations described on Nov 25, 2025 framed LockeT as a beneficiary. Financially, Q3 2025 results on Nov 13, 2025 showed revenue of $226,000 and ongoing losses. Today’s Hungary tender for the VIVO system fits the pattern of international commercial milestones that have previously triggered volatile but sometimes positive price reactions.

Market Pulse Summary

The stock surged +13.3% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +13.3% in the session following this news. A strong positive reaction aligns with prior instances where international commercialization or reimbursement milestones, such as the South African LockeT uptake and ASC reimbursement changes, triggered sizable moves. The Hungary tender adds another foothold for VIVO in Europe while shares were still trading well below the $4.15 200-day MA and 82.76% under the 52-week high. However, the company’s small revenue base and history of losses from recent filings remain important risk factors.

Key Terms

ventricular tachycardia, ablation, electrophysiology, non-invasive

4 terms

ventricular tachycardia medical

"offer non-invasive 3D localization of ventricular tachycardia prior to ablation"

A fast, abnormal heartbeat that starts in the heart’s lower chambers and can sharply reduce blood flow, potentially causing dizziness, fainting or, in severe cases, sudden collapse; picture an engine running so fast it loses power. For investors, ventricular tachycardia matters because demand for drugs, devices, diagnostic tests and emergency care tied to this condition affects clinical trial results, regulatory approvals, revenue prospects and legal or safety risks for healthcare companies.

ablation medical

"3D localization of ventricular tachycardia prior to ablation, is increasingly recognized"

Ablation is a medical procedure that removes, destroys, or isolates unwanted tissue using heat, cold, electricity, or chemicals to stop a disease or correct a problem—think of cutting out a faulty wire to restore a machine or removing a weed so a garden can recover. Investors care because ablation drives demand for specific devices, consumables and training, affects clinical trial and regulatory outcomes, and can change treatment patterns, reimbursement and market size for healthcare companies.

electrophysiology medical

"advanced solutions in the cardiac electrophysiology market, is proud to announce"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

non-invasive medical

"engineered to offer non-invasive 3D localization of ventricular tachycardia"

Non-invasive describes medical tests, treatments or devices that work from outside the body without cutting, inserting instruments, or implanting materials — for example external imaging, skin patches, or breath and saliva tests. For investors, non-invasive solutions often mean lower procedural risk, faster regulatory paths, easier manufacturing and broader patient acceptance, which can translate into quicker market uptake, lower costs and different revenue potential compared with invasive alternatives.

AI-generated analysis. Not financial advice.

FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary.

This achievement marks Catheter Precision’s inaugural installation in Hungary and reinforces its commitment to growth across Central and Eastern Europe. The tender was awarded in partnership with Fototronic, a well-established local distributor. Installation of the VIVO system is anticipated in the first quarter of 2026.

Fatih Ayoglu, Sales Manager for EMEA & APAC, stated, “This multi-year award at Szeged University Hospital represents a pivotal milestone for Catheter Precision. It not only underscores the clinical value of the VIVO system but also emphasizes our strategic expansion into emerging markets. Hungary is a key region for us, and this installation paves the way for wider adoption throughout Central Europe.”

The VIVO system, engineered to offer non-invasive 3D localization of ventricular tachycardia prior to ablation, is increasingly recognized in premier hospitals across Europe. The award from Szeged University Hospital follows several recent multi-year agreements in France, further solidifying the system’s esteemed reputation among electrophysiology experts. This tender achievement embodies Catheter Precision’s ongoing mission to provide innovative technologies that enhance patient outcomes and expand its global footprint.

About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that VIVO can bring and expectations regarding VIVO evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What did Catheter Precision (VTAK) announce on December 3, 2025 regarding Hungary?

Catheter Precision announced its VIVO system secured a multi-year tender at Szeged University Hospital, the company’s first installation in Hungary.

When will Catheter Precision install the VIVO system at Szeged University Hospital (VTAK)?

The company anticipates installation of the VIVO system in Q1 2026.

Who is Catheter Precision partnering with to supply VIVO to Szeged University Hospital (VTAK)?

Catheter Precision is partnering with local distributor Fototronic for the Hungarian tender.

What does the VIVO system do and why is the Szeged award significant for VTAK shareholders?

VIVO offers non-invasive 3D localization of ventricular tachycardia before ablation; the Szeged award signals broader European adoption and geographic expansion.

How does the Hungary tender relate to Catheter Precision’s recent European activity (VTAK)?

The Szeged tender follows several multi-year agreements in France, collectively reinforcing European clinical uptake of VIVO.